Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEGO Study: Mometasone furoate dry powder once daily in persistent mild-moderate asthma
2014-004926-17Phase 4
- Sponsor
- Merck & Co.
- Start
- Apr 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mometasone in asthma, sponsored by Merck & Co. Primary endpoint: Change in FEV1 from baseline.
02
Drugs
mometasone
03
Conditions
asthma
Beyond the preview
Go deeper on 2014-004926-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004926-17.